MS
IKT icon

Maven Securities’s Inhibikase Therapeutics IKT Stock Holding History

Maven Securities’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,833
Closed -$79K – 1225
2020
Q4 		$79K Buy
+1,833
New +$92.9K 0.01% 536

Other funds holding IKT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Maven Securities's IKT Position: Q1 2021 in Review

Maven Securities sold out of Inhibikase Therapeutics (IKT) in Q1 2021, closing a stake of 1,833 shares — an estimated $79K sold.

Maven Securities first reported a position in IKT in Q4 2020 and held it in 1 quarter. The position peaked at $79K in Q4 2020. 9 funds tracked by Wall St. Rank hold IKT as of Q1 2021.

  • Maven Securities reported no remaining Inhibikase Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Maven Securities sold 1,833 Inhibikase Therapeutics shares in Q1 2021, an estimated $79K.
  • Maven Securities first reported a position in Inhibikase Therapeutics in Q4 2020 and held it in 1 quarter.
  • Maven Securities's Inhibikase Therapeutics position peaked at $79K in Q4 2020.
  • 9 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2021.

Based on Maven Securities's 13F filing for Q1 2021, filed 17 May 2021.